Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

Open Access 01-03-2011 | Original Paper

S100B and homocysteine in the acute alcohol withdrawal syndrome

Authors: Dirk Wedekind, Karolin Neumann, Peter Falkai, Berend Malchow, Kirsten Rita Engel, Katja Jamrozinski, Ursula Havemann-Reinecke

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 2/2011

Abstract

Elevations of serum homocysteine levels are a consistent finding in alcohol addiction. Serum S100B levels are altered in different neuropsychiatric disorders but not well investigated in alcohol withdrawal syndromes. Because of the close connection of S100B to ACTH and glutamate secretion that both are involved in neurodegeneration and symptoms of alcoholism the relationship of S100B and homocysteine to acute withdrawal variables has been examined. A total of 22 male and 9 female inpatients (mean age 46.9 ± 9.7 years) with an ICD-10 diagnosis of alcohol addiction without relevant affective comorbidity were examined on admission and after 24, 48, and 120 h during withdrawal. S100B and homocysteine levels in serum were collected, and severity of withdrawal symptoms (AWS-scale), applied withdrawal medication, initial serum ethanol levels and duration of addiction were recorded. Serum S100B and homocysteine levels declined significantly (P < .05) over time. Both levels declined with withdrawal syndrome severity. Females showed a trend to a more intense decline in serum S100B levels compared to males at day 5 (P = .06). Homocysteine levels displayed a negative relationship to applied amount of clomethiazole (P < .05) and correlated with age of onset of addiction. No withdrawal seizures were recorded during the trial. As it is known for homocysteine, S100B revealed to decline rapidly over withdrawal treatment in alcoholism. This effect is more pronounced in female patients. S100B could be of relevance in the neurobiology of alcohol withdrawal syndromes. It may be indirectly related to the level of stress level or glutamatergic activity during alcohol withdrawal.

Mhatre MC, Pena G, Sieghart W, Ticku MK (1993) Antibodies specific for GABAA receptor alpha subunits reveal that chronic alcohol treatment down-regulates alpha-subunit-expression in rat brain regions. J Neurochem 61(5):1620–1625PubMedCrossRef

Tsai GE, Ragan P, Chang R, Chen S, Linnoila VM, Coyle JT (1998) Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry 155:726–732PubMed

Kril JJ, Halliday GM (1998) Brain shrinkage in alcoholics: a decade on and what have we learned? Prog Neurobiol 58:381–387CrossRef

Cravo ML, Gloria LM, Selhub J, Nadeau MR, Camilo ME, Resende MP, Cardoso JN, Leitao CN, Mira FC (1996) Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status. Am J Clin Nutr 63(2):220–224PubMed

Halsted CH (2001) Lifestyle effects on homocysteine and an alcohol paradox. Am J Clin Nutr 73(3):501–502PubMed

Hultberg B, Berglund M, Andersson A, Frank A (1993) Elevated plasma homocysteine in alcoholics. Alcohol Clin Exp Res 17:687–689PubMedCrossRef

Bleich S, Degner D, Wiltfang J, Maler JM, Niedmann P, Cohrs S, Mangholz A, Porzig J, Sprung R, Rüther E, Kornhuber J (2000) Elevated homocysteine levels in alcohol withdrawal. Alcohol Alcohol 35:351–354PubMed

Bleich S, Sperling W, Wiltfang J, Maler JM, Kornhuber J (2003) Excitatory neurotransmission in alcoholism. Fortschr Neurol Psychiatr 71(suppl 1):36–44

Bleich S, Hillemacher T (2009) Homocysteine, alcoholism and its molecular networks. Pharmacopsychiatry 42(suppl 1):102–109CrossRef

10.

Bleich S, Degner D, Bandelow B, von Ahsen N, Rüther E, Kornhuber J (2000) Plasma homocysteine is a predictor of alcohol withdrawal seizures. Neuroreport 11(12):2749–2752PubMedCrossRef

11.

Bleich S, Bandelow B, Javaheripour K, Müller A, Degner D, Wilhelm J, Havemann-Reinecke U, Sperling W, Rüther E, Kornhuber J (2003) Hyperhomocysteinaemia as a new risk factor for brain shrinkage in patients with alcoholism. Neurosci Lett 335:179–182PubMedCrossRef

12.

Lipton SA, Kim WK, Choi YB, Kumar S, D‘Emilia DM, Rayudu PV, Arnelle DR, Stamler JS (1997) Neuro-toxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 94:5923–5928PubMedCrossRef

13.

Hu J, Castets F, Guevara JL, Van Eldik LJ (1996) S100B stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. J Biol Chemistry 271(5):2543–2547CrossRef

14.

Barger SW, Van Eldik LJ, Mattson MP (1995) S100B protects hippocampal neurons from damage induced by glucose deprivation. Brain Res 677:167–170PubMedCrossRef

15.

Whitacker-Azmitia PM, Clarke C, Azmitia EC (1993) Localization of 5HT1a receptors to astroglial cells in adult rats: Implications for neuronal-glial interactions and psychoactive drug mechanisms of action. Synapse 14:201–205CrossRef

16.

Barger SW, Van Eldik LJ (1992) S100B stimulates calcium influxes in glial and neuronal cells. J Biol Chemistry 267(14):9689–9694

17.

Steiner J, Bernstein HG, Bielau H, Berndt A, Brisch R, Mawrin C, Keilhoff G, Bogerts B (2007) Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 8:2PubMedCrossRef

18.

Shirasawa N, Yamanouchi H (1999) Glucocorticoids induce glutamine synthetase in folliculostelate cells of rat pituitary glands in vivo and in vitro. J Anat 194:567–577PubMedCrossRef

19.

Ling SH, Tang YL, Jiang F, Wiste A, Guo SS, Weng YZ, Yang TS (2007) Plasma S-100B protein in Chinese patients with schizophrenia:comparison with healthy controls and effect of antipsychotics treatment. J Psychiatr Res 41(1–2):36–42PubMedCrossRef

20.

Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE (2009) Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia-original research and meta analysis. Psychiatry Res 167:66–72PubMedCrossRef

21.

Wiesmann M, Wandinger KP, Missler U, Eckhoff D, Rothermundt M, Arolt V, Kirchner H (1999) Elevated plasma levels of S100B protein in schizophrenic patients. Biol Psychiatry 45:1508–1511PubMedCrossRef

22.

Andreazza AC, Cassini C, Rosa AR (2007) Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 41:523–529PubMedCrossRef

23.

Arolt V, Petres M, Erfurth A, Wiesmann M, Missler U, Rudolf S, Kirchner H, Rothermundt M (2003) S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol 13(4):235–239PubMedCrossRef

24.

Rothermundt M, Arolt V, Wiesmann M, Missler U, Peters M, Rudolf S, Kirchner H (2001) S100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord 66:89–93PubMedCrossRef

25.

Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE (2002) S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport 13(13):1675–1678PubMedCrossRef

26.

Yang K, Xie GR, Hu YQ, Mao FQ, Su LY (2008) The effects of gender and number of depressive episodes on serum S100B levels in patients with major depression. J Neural Transm 115:1687–1694PubMedCrossRef

27.

Soyka M, Albus M, Immler B, Kathmann N, Hippius H (2001) Psychopathology in dual diagnosis and non-addicted schizophrenics—are there differences? Eur Arch Psychiatry Clin Neurosci 251(5):232–238PubMedCrossRef

28.

Mann K, Hintz T, Jung M (2004) Does psychiatric comorbidity in alcohol-dependent patients affect treatment outcome? Eur Arch Psychiatry Clin Neurosci 254(3):172–181PubMed

29.

Grabe HJ, Ahrens N, Rose HJ, Kessler C, Freyberger HJ (2001) Neurotrophic factor S100 beta in major depression. Neuropsychobiol 44(2):88–90CrossRef

30.

Druse MJ, Gillespie RA, Tajuddin NF, Rich M (2007) S100B-mediated protection against the proapoptotic effects of ethanol on fetal rhombencephalic neurons. Brain Res 1150:46–54PubMedCrossRef

31.

Liappas I, Tvavellass EO, Kariyannis C, Piperi C, Schulpis C, Papassotiriou I, Sodatos CR (2006) Effect of alcohol detoxification on serum S100B levels of alcohol-dependent individuals. In Vivo 20(5):675–680PubMed

32.

World Health Organisation (WHO) (1991) Tenth revision of the international classification of diseases, chapter V(F): mental and behavioural disorders (including disorders of psychological development). Clinical descriptions and diagnostic guidelines. World Health Organisation, Geneva

33.

Wetterling T, Kanitz RD, Besters B, Fischer D, Zerfass B, John U, Spranger H, Driessen M (1997) A new rating scale for the assessment of the alcohol withdrawal syndrome. Alcohol Alcohol 32(6):753–760PubMed

34.

Feuerlein W (1979) Early recognition and diagnosis of alcoholism. Bull Schw Akad Wiss 35(1–3):173–186

35.

Leite MC, Galland F, Brolese G, Guerra MC, Bortolotto JW, Freitas R, Almeida LM, Gottfried C, Goncalves CA (2008) A simple, sensitive and widely applicable ELISA for S100B: Methodological features of the measurement of this glial protein. J Neurosci Methods 169(1):93–99PubMedCrossRef

36.

Frantzen F, Faaren AL, Alfheim I, Nordhei AK (1998) Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 44(2):311–316PubMed

37.

Meisenzahl EM, Seifert D, Bottlender R, Teipel S, Zetzsche T, Jäger M, Koutsouleris N, Schmitt G, Scheuerecker J, Burgermeister B, Hampel H, Rupprecht T, Born C, Reiser M, Möller HJ, Frodl T (2010) Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. Eur Arch Psychiatry Clin Neurosci 260(2):127–137PubMedCrossRef

38.

Brandao LC, Hachul H, Bittencourt LR, Baracat EC, Tufik S, D‘Almeida V (2009) Effects of isoflavone on oxidative stress parameters and homocysteine in postmenopausal women complaining of insomnia. Biol Res 42:281–287PubMedCrossRef

39.

Martins PJ, Galdieri LC, Souza FG, Andersen ML, Benedito-Silva AA, Tufik S, D‘Almeida V (2005) Physiological variation in plasma total homocysteine concentration in rats. Life Sci 76(22):2621–2629PubMedCrossRef

40.

Lever M, Sizeland PCM, Frampton CM, Chambers ST (2004) Short and long-term variation of plasma glycine betaine concentrations in humans. Clin Biochem 37(3):84–90CrossRef

41.

Bleich S, Degner D, Sperling W, Bönsch D, Thürauf N, Kornhuber J (2004) Homocysteine as a neurotoxin in chronic alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 28:453–464PubMedCrossRef

42.

Kornhuber J, Kaiserauer CH, Kornhuber AW, Kornhuber ME (1987) Alcohol consumption and blood-cerebrospinal fluid barrier dysfunction in man. Neurosci Lett 79:218–222PubMedCrossRef

43.

Ehrlich S, Salbach-Andrae H, Weiss D, Burghardt R, Goldhahn K, Craciun EM, Franke L, Uebelhack R, Klapp BF, Lehmkuhl U (2008) S100B in underweight and weight-recovered patients with anorexia nervosa. Psychoneuroendocrinology 3(6):782–788CrossRef

Title: S100B and homocysteine in the acute alcohol withdrawal syndrome
Authors: Dirk Wedekind
Karolin Neumann
Peter Falkai
Berend Malchow
Kirsten Rita Engel
Katja Jamrozinski
Ursula Havemann-Reinecke
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 2/2011
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-010-0121-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

S100B and homocysteine in the acute alcohol withdrawal syndrome

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Patients’ attitudes toward side effects of antidepressants: an Internet survey

Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?

The illness and everyday living: close interplay of psychopathological syndromes and psychosocial functioning in chronic schizophrenia

Postmortem proteomic analysis in human amygdala of drug addicts: possible impact of tubulin on drug-abusing behavior

The functional sequelae of schizophrenia: consequences of long-term pharmacotherapy and the neurobiology of addiction

Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder